ICVTS Click here to locate an Ethicon representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Interact CardioVasc Thorac Surg 2008;7:235-239. doi:10.1510/icvts.2007.161356
© 2008 European Association of Cardio-Thoracic Surgery

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Haydar Yasa
Cengiz Ozbek
Ali Gurbuz
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yakut, N.
Right arrow Articles by Gurbuz, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yakut, N.
Right arrow Articles by Gurbuz, A.
Related Collections
Right arrow Peripheral vascular

Institutional report - Vascular general

The influence of levosimendan and iloprost on renal ischemia–reperfusion: an experimental study

Necmettin Yakut, Haydar Yasa*, Banu Bahriye Lafci, Ragip Ortac, Engin Tulukoglu, Murat Aksun, Cengiz Ozbek and Ali Gurbuz

Department of Cardiovascular Surgery, Atatürk Education and Research Hospital, Izmir, Turkey

*Corresponding author. 2/11 sok. No: 7 D: 18 Oyak Sitesi, Izmir, Turkey. Fax: +90 232 2434848.

E-mail address: hyasa20{at}yahoo.com (H. Yasa).

The effects of iloprost on ischemia–reperfusion injury have been studied on the skeletal, muscle, liver, myocardium, kidney, and spinal cord. However, no sufficient data exist about effects of levosimendan on renal ischemia–reperfusion injury. The purpose of this experimental study was to investigate and compare effectiveness of levosimendan and iloprost on renal injury induced by ischemia and reperfusion. Fifty rabbits were divided into five groups. Levosimendan was continuously infused starting half an hour before the cross-clamp. Cross-clamp time was one hour. After one hour ischemia, levosimendan was continued for 4 h in Group A whereas Group B took iloprost in the same protocol. Group C was the control group which did not receive any medication. Group D was sham group and Group E was medicated both iloprost and levosimendan. Renal tissues were histologically and biochemically evaluated. The histological scores were obtained according to presence of tubuler necrosis and atrophy, regenerative atypia, hydropic degeneration (Group A vs. Group C<0.001, Group B vs. Group C<0.001, Group D vs. Group C<0.01, Group E vs. Group C<0.001). Mean malondialdehyde levels were 114±12 nmol/g tissue; in Group A 121±13 nmol/g tissue, in Group B 134±13 nmol/g tissue, in Group E 130±11 nmol/g tissue, in Group D 134±11 nmol/g tissue (Group A vs. Group B; P=0.003, Group B vs. Group D; P=0.132, Group A vs. Group E; P=0.132). Malondialdehyde levels and histologic scores of all of the groups were significantly different from the control group. Iloprost and pentoxyfillin reduced renal ischemia–reperfusion injury in rabbit model. There was no significant difference between these two medications.

Key Words: Iloprost; Levosimendan; Ischemia/reperfusion injury; Rabbit kidney







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 European Association for Cardio-thoracic Surgery